The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.
Lillian L. Siu
Research Funding - Roche
Antoine Italiano
No relevant relationships to disclose
Wilson H. Miller
Consultant or Advisory Role - Roche
Jean-Yves Blay
Honoraria - Roche
Research Funding - Roche
Jourik A. Gietema
Research Funding - Roche
Yung-Jue Bang
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Linda R. Mileshkin
Consultant or Advisory Role - Roche Australia Ovarian Cancer Advisory Board (U)
Hal W. Hirte
No relevant relationships to disclose
Monica Reckner
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Brian Higgins
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Lori Jukofsky
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Steven Blotner
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Jianguo Zhi
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche TCRC
Steven Middleton
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Gwen L. Nichols
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche
Lin Chi Chen
Employment or Leadership Position - Roche TCRC
Stock Ownership - Roche